What is HC Wainwright's Forecast for IO Biotech Q2 Earnings?

IO Biotech, Inc. (NASDAQ:IOBT - Free Report) - Stock analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of IO Biotech in a report issued on Wednesday, May 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.38) for the quarter, up from their previous estimate of ($0.51). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for IO Biotech's current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for IO Biotech's Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.01) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.25) EPS and FY2029 earnings at $0.03 EPS.

Separately, Piper Sandler raised IO Biotech to a "strong-buy" rating in a research report on Wednesday, March 12th.

IO Biotech Stock Up 0.8%

Shares of IOBT traded up $0.01 during mid-day trading on Monday, reaching $1.21. 154,436 shares of the company's stock were exchanged, compared to its average volume of 273,734. The company has a 50-day simple moving average of $0.99 and a two-hundred day simple moving average of $0.93. The company has a market cap of $79.72 million, a price-to-earnings ratio of -0.88 and a beta of 0.09. IO Biotech has a 52-week low of $0.66 and a 52-week high of $1.73.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in shares of IO Biotech in the first quarter worth about $26,000. XTX Topco Ltd acquired a new stake in IO Biotech during the 4th quarter valued at approximately $26,000. Vontobel Holding Ltd. purchased a new stake in IO Biotech during the 4th quarter worth approximately $30,000. Renaissance Technologies LLC raised its position in shares of IO Biotech by 22.5% in the 4th quarter. Renaissance Technologies LLC now owns 118,800 shares of the company's stock valued at $109,000 after purchasing an additional 21,800 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of IO Biotech during the 4th quarter valued at approximately $249,000. 54.76% of the stock is owned by institutional investors and hedge funds.

About IO Biotech

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.